Qube Research & Technologies (QRT)
OVID icon

Qube Research & Technologies (QRT)’s Ovid Therapeutics OVID Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-94,301
Closed -$209K – 3907
2026
Q1 		$209K Buy
94,301
+40,350
+75% +$72.1K ﹤0.01% 2944
2025
Q4 		$87.9K Buy
53,951
+28,674
+113% +$44.2K ﹤0.01% 3205
2025
Q3 		$32.9K Sell
25,277
-47,464
-65% -$41.1K ﹤0.01% 3234
2025
Q2 		$24K Buy
+72,741
New +$21.9K ﹤0.01% 3241
2024
Q2 		– Sell
-54
Closed -$165 – 4479
2024
Q1 		$165 Buy
+54
New +$181 ﹤0.01% 4152
2022
Q1 		– Sell
-13,989
Closed -$45K – 2845
2021
Q4 		$45K Buy
+13,989
New +$47.9K ﹤0.01% 2277
2020
Q2 		– Sell
-22,442
Closed -$67K – 1915
2020
Q1 		$67K Sell
22,442
-228,820
-91% -$771K ﹤0.01% 1003
2019
Q4 		$1.04M Buy
+251,262
New +$793K 0.03% 590

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Qube Research & Technologies (QRT)'s OVID Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 94,301 shares — an estimated $209K sold.

Qube Research & Technologies (QRT) first reported a position in OVID in Q4 2019 and held it in 8 quarters. The position peaked at $1.04M in Q4 2019. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 94,301 Ovid Therapeutics shares in Q2 2026, an estimated $209K.
  • Qube Research & Technologies (QRT) first reported a position in Ovid Therapeutics in Q4 2019 and held it in 8 quarters.
  • Qube Research & Technologies (QRT)'s Ovid Therapeutics position peaked at $1.04M in Q4 2019.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.